M&A / Deals

Novartis-backed Sidewinder collects $137M series B to strike at difficult-to-treat tumors

BioSpace

Sidewinder Therapeutics' bispecific antibody-drug conjugates target pairs of receptors found on cancer cells, which the company claims improves their specificity and minimizes off-target effects.

M&A / Deals Oncology Read full story

pharminent April 9, 2026 (Last updated: April 9, 2026)

BioSpace

Sidewinder Therapeutics’ bispecific antibody-drug conjugates target pairs of receptors found on cancer cells, which the company claims improves their specificity and minimizes off-target effects.

M&A / Deals Oncology Read full story

Related Stories

Fulcrum exploring a potential sale after FDA sidelined its sickle cell drug

CordenPharma inks AmbioPharm buyout to continue peptide production expansion

Servier wagers $2.65bn on Edgewise muscular dystrophy drug

You May Have Missed

Eli Lilly issues data sharing ultimatum to 340B hospitals

Fulcrum exploring a potential sale after FDA sidelined its sickle cell drug

ASCO 2026: Kelonia presents positive in vivo CAR-T data in multiple myeloma

ASCO26: In vivo oncology approaches continue to show promise